Monoaminergic modulation of behavioural and electrophysiological indices of error processing
- 560 Downloads
Error processing is a critical executive function that is impaired in a large number of clinical populations. Although the neural underpinnings of this function have been investigated for decades and critical error-related components in the human electroencephalogram (EEG), such as the error-related negativity (ERN) and the error positivity (Pe), have been characterised, our understanding of the relative contributions of key neurotransmitters to the generation of these components remains limited.
The current study sought to determine the effects of pharmacological manipulation of the dopamine, noradrenaline and serotonin neurotransmitter systems on key behavioural and event-related potential correlates of error processing.
A randomised, double-blinded, placebo-controlled, crossover design was employed. Monoamine levels were manipulated using the clinically relevant drugs methylphenidate, atomoxetine and citalopram, in comparison to placebo. Under each of the four drug conditions, participants underwent EEG recording while performing a flanker task.
Only methylphenidate produced significant improvement in performance accuracy, which was without concomitant slowing of reaction time. Methylphenidate also increased the amplitude of an early electrophysiological index of error processing, the ERN. Citalopram increased the amplitude of the correct-response negativity, another component associated with response processing.
The effects of methylphenidate in this study are consistent with theoretical accounts positing catecholamine modulation of error monitoring. Our data suggest that enhancing catecholamine function has the potential to remediate the error-monitoring deficits that are seen in a wide range of psychiatric conditions.
KeywordsAtomoxetine Citalopram Dopamine Error positivity Error processing Error-related negativity Methylphenidate Noradrenaline Performance monitoring Serotonin
This work was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) (569532) to MAB. MAB is supported by a Career Development Award from the NHMRC, Australia. We would like to thank the Wesley Hospital Pharmacy for dispensing the drugs associated with this project.
Conflict of interest
Both LSN and MAB have received reimbursement from Lilly Pharmaceuticals for conference travel expenses and for speaking at conferences. The author MAB has received speaker's fees from Janssen-Cilag. The author LSN has received speaker's fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim and Janssen-Cilag. The authors JJMB, RGO and AJD report no biomedical financial interests or potential conflicts of interest.
- Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Brain Res Brain Res Rev 60:1111–1120Google Scholar
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711PubMedCrossRefGoogle Scholar
- Chamberlain SR, Hampshire A, Muller U, Rubia K, Del Campo N, Craig K, Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW, Sahakian BJ (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65:550–555PubMedCrossRefGoogle Scholar
- Herrmann MJ, Mader K, Schreppel T, Jacob C, Heine M, Boreatti-Hummer A, Ehlis AC, Scheuerpflug P, Pauli P, Fallgatter AJ (2010) Neural correlates of performance monitoring in adult patients with attention deficit hyperactivity disorder (ADHD). World J Biol Psychiatry 11:457–464PubMedCrossRefGoogle Scholar
- Kramer UM, Cunillera T, Camara E, Marco-Pallares J, Cucurell D, Nager W, Bauer P, Schule R, Schols L, Rodriguez-Fornells A, Munte TF (2007) The impact of catechol-O-methyltransferase and dopamine D4 receptor genotypes on neurophysiological markers of performance monitoring. J Neurosci 27:14190–14198PubMedCrossRefGoogle Scholar
- Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79–95PubMedCrossRefGoogle Scholar
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33, quiz 34-57PubMedGoogle Scholar